This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period. Read More

1) History of chronic stable, NYHA class II to IV CHF 2) NT-proBNP 600 - 6000 3) LVEF of <40% assessed within 12 months before randomization

Study to assess the effect of dapagliflozin as compared with placebo in patients with heart failure who have been stabilized during hospitalization for acute heart failure. Patients will be followed for a maximum of 2 months. Read More

1. Currently hospitalized with AHF with symptoms of AHF.
2. LVEF <40% within the past 12 months
3. Elevated NT-proBNP, >1600 pg/ml
4. > 18 years of age
5. eGFR >30

-Adults ages 18-80
-Has a single unruptured target intracranial aneurysm (IA) located on the internal carotid artery (ICA) or its branches.

This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR). The purpose of this study is to look at the safety and effectiveness of this new investigational device compared to the standard medical treatment. Read More

Adults ages 18+
Diagnosed with Tricuspid Regurgitation/Insufficiency

This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More

Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).

This study enrolls people who have mitral regurgitation (MR). Mitral regurgitation happens when the heart’s mitral valve does not close tightly. The purpose of this trial is to evaluate a new investigational device called the Tendyne™ Mitral Valve System. The Tendyne Mitral Valve System is designed for the treatment of a diseased, damaged or malfunctioning mitral valve. This trial will collect information on how safe and effective this device is to treat a leaking mitral valve compared to the commercially available MitraClip® System. Read More

-Adults ages 18+.
-Have symptomatic, moderate-to-severe/severe mitral regurgitation (MR) or severe mitral annular calcification (MAC)
-Your medical providers have decided a transcatheter therapy is more appropriate than open surgery.

This study is for people undergoing surgery for mitral regurgitation (MR). Mitral regurgitation is a condition when your heart’s mitral valve does not close tightly which causes blood to flow backwards in your heart. The purpose of this study is to learn how safe and effective one value repair system is (the PASCAL System, an investigational device) compared to another one (the MitraClip System). Read More

Adults ages 18+.
Have severe degenerative mitral regurgitation, and are considered prohibitive risk for mitral valve surgery by your heart team.

We are enrolling people who are undergoing a cardiac neurological procedure. The purpose of this study is to collect information from a medical device used in these procedures called the VISOR device. We will collect information before and after a person has a cardio-cerebrovascular procedure to see how well the device detects neurological injury from the procedure. Read More

-Adults ages 18+.
-Undergoing cardiovascular procedures including trans-aortic valve replacement (TAVR), left atrial appendage closure, electrophysiological ablation, coronary artery bypass grafting (CABG) and valve replacement surgery, with the application of Cerebrotech VISOR.

This is a research study which will determine whether a series of tests can predict the Read More

• Coronary artery disease (by cardiac catheterization or definite myocardial infarction)
• ICD implantation for the primary prevention of SCA
• Optimal medical therapy for heart failure [angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARA)].

This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR) and have Heart Failure symptoms which are not under control despite treatment with current available therapies. The purpose of this study is to compare a new investigational (experimental) device plus optimal drug therapy with optimal drug therapy alone. Read More

Adults ages 18+
Diagnosed with moderate or greater Tricuspid Regurgitation/Insufficiency with Heart Failure symptoms